REGENXBIO Inc. RGNX
At closeNov 4, 2026, 5:05 AM EST
Pre-market · Nov 4, 5:05 AM ET
- YTD
- -47.01%
- 1 year
- -36.36%
- Market cap
- 503.68M
- Revenue (ttm)
- 84.33M
- Profit margin
- -283.19%
- EPS (ttm)
- -3.78
- Shares out
- 49.55M
- Forward P/E
- -6.83
- YTD return
- -47.01%
- 1-year return
- -36.36%
- Volume
- 854.95K
- Avg volume
- 1.36M
- Open
- 7.29
- Previous close
- 7.16
- Day's range
- 7.27 – 7.65
- 52-week range
- 5.46 – 16.19
- Beta
- 1.23
- Analysts
- Strong Buy
- Price target
- 37.64 (+393.3%)
2Y -1.13 (-12.90%)
Key statistics
- Enterprise value
- 267.88M
- PEG ratio
- 0.00
- Price / sales
- 4.34
- Price / book
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -16.30%
- Free cash flow
- -95.26M
- Total cash
- 255.46M
- Total debt
- 145.81M
- Return on equity
- -71.87%
- Short % of float
- 13.88%
- 50-day average
- 9.58
- 200-day average
- 13.24
Analyst view
Consensus: strong buy
- Target (low)
- 22.00
- Target (mean)
- 37.64
- Target (high)
- 52.00
- Strong buy5
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.16 | -1.17 | -0.01 | -0.86% |
| Aug 1, 2024 | Jun 1, 2024 | -1.29 | -1.05 | +0.24 | +18.60% |
| May 8, 2024 | Mar 1, 2024 | -1.28 | -1.38 | -0.10 | -7.81% |
| Feb 27, 2024 | Dec 1, 2023 | -1.27 | -1.43 | -0.16 | -12.60% |
| Nov 8, 2023 | Sep 1, 2023 | -1.44 | -1.41 | +0.03 | +2.08% |
| Aug 2, 2023 | Jun 1, 2023 | -1.26 | -1.66 | -0.40 | -31.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | RBC Capital | reit | Outperform | Outperform |
| Nov 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 22, 2024 | Chardan Capital | main | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regenxbio.com
News
REGENXBIO to Participate in Stifel 2026 Healthcare Conference 
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy? 
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights 
Full Transcript: Regenxbio Q2 2026 Earnings Call 
Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22
Your note
Sign in to keep a note on RGNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAN MITCHELL | Chief Financial Officer | Stock Award(Grant) | Sep 15, 2024 | 58,869 |
| CHRISTMAS PATRICK J. II | Officer | Stock Award(Grant) | Jul 31, 2024 | 172,205 |
| DANOS OLIVIER | Officer | Stock Award(Grant) | Jul 31, 2024 | 185,083 |
| KARABELAS ARGERIS N | Director | Conversion of Exercise of derivative security | Sep 30, 2024 | 11,286 |
| MIGAUSKY GEORGE V | Director | Stock Award(Grant) | May 30, 2024 | 11,286 |
| MILLS KENNETH THOMAS | Director | Conversion of Exercise of derivative security | Aug 7, 2024 | 444,351 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.85% | 8,844,466 | 65.27M | Sep 29, 2024 |
| Redmile Group, LLC | 9.88% | 4,892,902 | 36.11M | Sep 29, 2024 |
| Vanguard Group Inc | 8.82% | 4,368,991 | 32.24M | Sep 29, 2024 |
| State Street Corporation | 5.62% | 2,782,883 | 20.54M | Sep 29, 2024 |
| JP Morgan Chase & Company | 5.00% | 2,477,311 | 18.28M | Sep 29, 2024 |
| Morgan Stanley | 2.72% | 1,349,876 | 9.96M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 5.86% | 2,902,939 | 21.42M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.83% | 1,400,445 | 10.34M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.39% | 1,183,646 | 8.74M | Oct 30, 2024 |
| JP Morgan Small Cap Growth Fund | 2.35% | 1,162,623 | 8.58M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.78% | 880,902 | 6.50M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.48% | 735,639 | 5.43M | Sep 29, 2024 |